Chromanone compound containing 1, 3-oxazole fragment as well as synthesis method and application of chromanone compound

Preparation of chromanone compounds containing 1,3-oxazole fragments through a multi-component reaction system solved the defects of the synthesis method in the prior art, achieved efficient and gentle synthesis, and the compound showed significant results on tumor cells. Inhibiting effects provide new materials for anti-tumor drugs.

CN118908948APending Publication Date: 2024-11-08CHONGQING UNIV OF ARTS & SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410819838.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing synthesis method of C2 alkyl ketone synthesis has problems with excessive additive use, noble metal catalyst dependence, high temperature reaction conditions and limited substrate range, and there is a lack of reports on ketone ketone containing 1,3-oxazole fragments. .

Method used

Using a multi-component reaction system, the chromanone ketone compounds containing 1,3-oxazole fragments were quickly prepared by one-pot method to avoid excessive additives, without precious metals, and have strong applicability. The three-component reaction strategy was used to catalyze Lewis acid. Includes Michael addition/alkyne cyclization process.

Benefits of technology

Successfully prepared Chemone compounds containing 1,3-oxazole fragments with potential for anti-tumor activity were prepared, which showed significant inhibitory effects on human prostate and colon cancer cells, reduced survival rate, and mild synthesis method and substrate Strong applicability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908948A_ABST
    Figure CN118908948A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicinal chemistry, in particular to a chromanone compound containing a 1, 3-oxazole fragment and a synthesis method and application thereof.According to the chromanone compound containing the 1, 3-oxazole fragment, substituted chromanone, amine and N-propargyl amide serve as raw materials, and the chromanone compound containing the 1, 3-oxazole fragment is obtained through a lewis acid catalysis three-component reaction strategy. The chromanone compound containing the 1, 3-oxazole fragment is rapidly prepared by a one-pot method through the processes of Michael addition / alkyne cyclization and the like. The chromanone compound containing the 1, 3-oxazole fragment is constructed on the basis of a novel multi-component reaction strategy for the first time, A549 and DU145 cells are selected for antitumor activity evaluation, and it is found that the chromanone compound has a high inhibition effect on human prostate cancer cells DU145 and can be used for preparing antitumor drugs. In the synthesis method, no excessive additive is used, no noble metal catalyst participates, the reaction condition is mild, and the method has the characteristics of high substrate applicability and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a chromanone compound containing a 1,3-oxazole fragment, a synthesis method and application thereof. Background Art

[0002] There are a large number of heterocyclic compounds widely distributed in nature, which play an important role in the development and growth of organisms. In the early 19th century, heterocyclic compounds were mostly obtained by extracting natural products, but the yield of the compounds obtained was very low, the purity was not high, and the price was expensive. With the development of organic synthesis technology, in order to make full use of heterocyclic compounds, chemists began to carry out large-scale artificial synthesis of heterocyclic compounds, which have been widely used, including biomedicine, energy storage materials, biomimetic materials, high-performance dyes, etc.

[0003] Among them, chromanones are widely distributed in natural products and bioactive compounds, especially C2 alkyl chromanones, such as the natural product Flindersia laevicarpa, SIRT2 inhibitors, antibacterial agents, antifungal agents, etc. At present, the synthesis methods of C2 alkyl chromanones mainly rely on oxa-Michael addition reactions based on organometallic reagents, reductive strategies of silane or metal catalysts / hydrogen, and transition metal-catalyzed cyclization. However, most of the reported methods have problems such as excessive use of additives, use of precious metal catalysts, high temperature reaction conditions and limited substrate range. With the continuous development of synthetic chemistry, the development of synthetic strategies with high atom economy and reaction economy has attracted more and more attention from organic chemists and pharmacologists.

[0004] In addition, oxazole is also an important heterocyclic compound with important biological activity and great application value, such as antidiabetic drug AD-5061, antimycobacterial texaline, anti-inflammatory and bronchodilator 4-aminooxazole, etc. Fragment-based drug design (FBDD) is an important means of drug discovery, and there are no reports on chromanone compounds containing 1,3-oxazole fragments. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a chromanone compound containing a 1,3-oxazole fragment and a synthesis method and application thereof, adopt a multi-component reaction system, and use a one-pot method to quickly prepare a chromanone compound containing a 1,3-oxazole fragment, avoiding the use of excessive additives, and without the involvement of precious metals and strong applicability; this type of compound can be used for anti-tumor activity research and for the preparation of anti-tumor drugs.

[0006] The present invention solves the above technical problems by the following technical means:

[0007] In a first aspect, the present invention provides a chromanone compound containing a 1,3-oxazole fragment, the general structural formula of the compound is as follows:

[0008]

[0009] Wherein, Ar is a phenyl group which is unsubstituted or substituted with a first substituent, the first substituent substitution includes mono-substitution or di-substitution, and the first substituent is selected from halogen and an alkyl group having 1 to 6 carbon atoms;

[0010] R 1 A phenyl group substituted with a second substituent, or a straight-chain or branched alkyl group having 3 to 10 carbon atoms, or a cycloalkyl group having 3 to 10 carbon atoms, wherein the second substituent includes di-substitution or tri-substitution, and the second substituent is selected from an alkyl group having 1 to 6 carbon atoms;

[0011] R 2 It is one of alkyl, aryl and heteroaryl.

[0012] In combination with the first aspect, in some embodiments, Ar is selected from phenyl, 6-methylphenyl, 6-bromophenyl, 6-chlorophenyl, 6-chloro-7-methylphenyl, 6-fluorophenyl;

[0013] R 1 Selected from tert-butyl, isopropyl, cyclopropyl, adamantyl, 2,6-dimethylphenyl, 2-tert-butylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl;

[0014] R 2 Selected from 4-iodophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, piperonyl, n-heptyl, cyclohexyl, 2-thienyl, 4-trifluoromethylphenyl.

[0015] In combination with the first aspect, in some embodiments, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0016] Alternatively, the compound is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((isopropylamino)methylene)benzopyran-4-one;

[0017] Alternatively, the compound is (Z)-3-((cyclopropylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0018] Alternatively, the compound is (Z)-3-((((3s,5s,7s)-adamantan-1-yl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0019] Alternatively, the compound is (Z)-3-(((2,6-dimethylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0020] Alternatively, the compound is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0021] Alternatively, the compound is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((m-trimethylamino)methylene)benzopyran-4-one;

[0022] Alternatively, the compound is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0023] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-6-methylbenzopyran-4-one;

[0024] Alternatively, the compound is (Z)-6-bromo-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0025] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0026] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-7-methylbenzopyran-4-one;

[0027] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-fluoro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0028] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-fluorophenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0029] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0030] Alternatively, the compound is (Z)-2-((2-(benzo[d][1,3]dioxol-5-yl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one;

[0031] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-heptyloxazol-5-yl)methyl)benzopyran-4-one;

[0032] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-cyclohexyloxazol-5-yl)methyl)benzopyran-4-one;

[0033] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(thiophen-2-yl)oxazol-5-yl)methyl)benzopyran-4-one;

[0034] Alternatively, the compound is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)-benzopyran-4-one;

[0035] Alternatively, the compound is (Z)-3-((m-trimethylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0036] Alternatively, the compound is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0037] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(p-tolueneacetyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one;

[0038] Alternatively, the compound is (Z)-4-(5-((3-((tert-butylamino)methylene)-4-oxo-2-yl)methyl)oxazol-2-yl)-N,N-dipropylbenzenesulfonamide;

[0039] Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(((8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-17-yl)ethynyl)phenyl)oxazol-5-yl)methyl)chrom-4-one;

[0040] Alternatively, the compound is (Z)-2-((2-(4-((3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethynyl)phenyl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one.

[0041] In a second aspect, the present invention provides a method for synthesizing a chromanone compound containing a 1,3-oxazole fragment, the method being as follows:

[0042]

[0043] Wherein, Ar is selected from phenyl, 6-methylphenyl, 6-bromophenyl, 6-chlorophenyl, 6-chloro-7-methylphenyl, 6-fluorophenyl;

[0044] R 1 Selected from tert-butyl, isopropyl, cyclopropyl, adamantyl, 2,6-dimethylphenyl, 2-tert-butylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl;

[0045] R 2 Selected from 4-iodophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, piperonyl, n-heptyl, cyclohexyl, 2-thienyl, 4-trifluoromethylphenyl.

[0046] In conjunction with the second aspect, in some embodiments, the synthesis method is as follows:

[0047] Compound 1 is added to a mixed solution of compound 2 and dichloroethane, and stirred at room temperature for 5 to 20 minutes. Compound 3 and Zn(OTf)2 are then added to the reaction system, and the mixture is reacted at 90 to 110°C for 3 to 6 hours. The reaction is detected by thin layer chromatography. After the reaction is completed, dichloromethane is added, and the mixture is washed with saturated brine. The organic phase is dried over anhydrous sodium sulfate to obtain a crude product, which is separated using a silica gel column to obtain a chromanone compound containing a 1,3-oxazole fragment.

[0048] In combination with the second aspect, in some embodiments, the molar ratio of Compound 1, Compound 2 and Compound 3 is 1:1:(1.1-1.3).

[0049] In a third aspect, the present invention provides the use of the chromanone compounds containing 1,3-oxazole fragments according to the first aspect or the chromanone compounds containing 1,3-oxazole fragments synthesized by the synthesis method of the second aspect in the preparation of anti-tumor drugs.

[0050] The chromanone compounds containing 1,3-oxazole fragments of the present invention use substituted chromone, amine and N-propargyl amide as raw materials, adopt Lewis acid catalyzed three-component reaction strategy, and undergo Michael addition / alkyne cyclization and other processes to quickly prepare the chromanone compounds containing 1,3-oxazole fragments in a one-pot method.

[0051] The present invention is the first to construct chromanone compounds containing 1,3-oxazole fragments based on a novel multi-component reaction strategy, and selects A549 and DU145 cells for anti-tumor activity evaluation. It is found that the chromanone compounds have a significant inhibitory effect on the cell activity of human prostate cancer cells DU145 and human colon cancer cells HCT116. After treatment with chromanone compounds, the survival rate of human prostate cancer cells DU145 is as low as 47%, and the survival rate of human colon cancer cells HCT116 is as low as 64%.

[0052] In the synthesis method of the present invention, no excessive additives are used, no precious metal catalyst is involved, the reaction conditions are mild, and the method has the characteristics of strong substrate applicability and the like. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 is the general structural formula of the chromanone compound containing 1,3-oxazole fragment of the present invention;

[0054] Figure 2 This is a synthetic route for chromanone compounds containing 1,3-oxazole fragments. DETAILED DESCRIPTION

[0055] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0056] In the following examples, if no specific conditions are specified, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. The raw materials, equipment or instruments used, if no manufacturer is specified, are all conventional products that can be purchased on the market.

[0057] The present invention discloses a novel method for efficiently constructing chromanone compounds containing 1,3-oxazole fragments by three groups of reactions catalyzed by Lewis acids. The method does not use excessive additives, does not involve precious metal catalysts, has mild reaction conditions, and has the characteristics of strong substrate applicability. A series of novel chromanone compounds in the present invention are selected to evaluate the anti-tumor activity of A549 and DU145 cells, and it is found that the chromanone compounds show a strong inhibitory effect on human prostate cancer cell DU145, and can be used to prepare anti-tumor drugs.

[0058] The chromanone compound containing 1,3-oxazole fragment of the present invention has the following general structural formula: Figure 1 The synthesis method is as shown in Figure 2 As shown, the specific synthesis method is as follows:

[0059] Compound 1 is added to a mixed solution of compound 2 and dichloroethane, stirred at room temperature for 5 to 20 minutes, preferably stirred for 10 minutes, then compound 3 and Zn(OTf)2 are added to the reaction system, reacted at a temperature of 90 to 110°C for 3 to 6 hours, preferably at a temperature of 100°C for 5 hours, and the reaction is detected by thin layer chromatography. After the reaction is completed, dichloromethane liquid is added three times for extraction, and then washed with saturated brine. The organic phase is dried with anhydrous sodium sulfate to obtain a crude product, which is separated by a silica gel column to obtain a chromanone compound containing a 1,3-oxazole fragment. Wherein, the molar ratio of compound 1, compound 2 and compound 3 is 1:1:(1.1 to 1.3), and the molar ratio of compound 1, compound 2 and compound 3 is preferably 1:1:1.2.

[0060] Wherein, Ar is a phenyl group which is unsubstituted or substituted with a first substituent, the first substituent substitution includes mono-substitution or di-substitution, and the first substituent is selected from halogen and an alkyl group having 1 to 6 carbon atoms; R 1 is a phenyl group substituted with a second substituent, or a straight or branched alkyl group with 3 to 10 carbon atoms, or a cycloalkyl group with 3 to 10 carbon atoms, wherein the second substituent includes di-substitution or tri-substitution, and the second substituent is selected from an alkyl group with 1 to 6 carbon atoms; R 2 It is one of alkyl, aryl and heteroaryl.

[0061] In some embodiments, Ar is selected from phenyl, 6-methylphenyl, 6-bromophenyl, 6-chlorophenyl, 6-chloro-7-methylphenyl, 6-fluorophenyl; R 1 is selected from tert-butyl, isopropyl, cyclopropyl, adamantyl, 2,6-dimethylphenyl, 2-tert-butylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl; R 2Selected from 4-iodophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, piperonyl, n-heptyl, cyclohexyl, 2-thienyl, 4-trifluoromethylphenyl.

[0062] For details, please refer to Examples 1-26. In the following examples, DCE represents dichloroethane.

[0063] Example 1

[0064] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0065] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 81%.

[0066] 1 H NMR (400MHz, CDCl3) δ10.43 (d, J=13.1Hz, 1H), 7.91 (dd, J=7.7, 1.6Hz, 1H), 7.79(d,J=8.5Hz,2H),7.71(d,J=8.5Hz,2H),7.45–7.32(m,1H),7.04(t,J=7 .2Hz,1H),6.91(t,J=3.9Hz,2H),6.72(d,J=13.2Hz,1H),5.15(t,J=7.1Hz,1 H), 3.31 (dd, J=15.1, 7.4Hz, 1H), 3.00 (dd, J=15.1, 6.8Hz, 1H), 1.23 (s, 9H). 13C NMR (100MHz, CDCl3) δ180.03,160.40,156.51,149.18,146.48,137.97,133.85,127.55,126.99,1 26.39,126.13,123.26,121.60,117.79,99.41,96.50,52.46,33.27,29.95.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 24 IN2O3 + 515.0827;Found 515.0825.

[0067] Example 2

[0068] In this embodiment, Ar is phenyl, R 1 is isopropyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((isopropylamino)methylene)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0069] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of isopropylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((isopropylamino)methylene)benzopyran-4-one was finally obtained with a yield of 77%.

[0070] 1H NMR (400MHz, CDCl3) δ9.99 (dd, J=12.1, 7.6Hz, 1H), 7.84 (dd, J=7.8, 1.7Hz, 1H), 7.76–7.70 (m,2H),7.67–7.63(m,2H),7.32(ddd,J=8.8,7.4,1.7Hz,1H),7.02–6.93(m,1H),6.87–6.7 9(m,2H),6.60(d,J=12.9Hz,1H),5.06(dd,J=7.4,6.7Hz,1H),3.34(dd,J=13.5,6.7Hz,1H) ,3.24(dd,J=15.2,7.7Hz,1H),2.92(dd,J=15.2,6.3Hz,1H),1.14(dd,J=11.1,6.5Hz,6H). 13 C NMR (100MHz, CDCl3) δ180.35,160.43,156.58,149.27,148.60,138.03,133.91,127.62,126.81, 126.19,123.25,121.63,117.80,99.57,96.66,50.40,33.31,23.79,23.56.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 22 IN2O3 + 501.0670;Found 501.0667.

[0071] Example 3

[0072] In this embodiment, Ar is phenyl, R 1 is cyclopropyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((cyclopropylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0073] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of cyclopropylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl) benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product Z)-3-((cyclopropylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 73%.

[0074] 1 H NMR (400MHz, CDCl3) δ9.99 (d, J=12.1Hz, 1H), 7.90 (dd, J=7.8, 1.6Hz, 1H), 7.82–7.78 (m ,2H),7.72(d,J=8.5Hz,2H),7.43–7.36(m,1H),7.07–7.01(m,1H),6.90(d,J=10.3Hz,2H ),6.75(d,J=12.4Hz,1H),5.13(dd,J=7.6,6.5Hz,1H),3.31(dd,J=15.2,7.8Hz,1H),2. 99(dd,J=15.2,6.3Hz,1H),2.73(d,J=3.6Hz,1H),0.75–0.65(m,2H),0.65–0.50(m,2H). 13 C NMR (100MHz, CDCl3) δ180.81,156.77,150.66,149.10,138.01,134.14,127.58,126.96,126 .34,123.09,121.63,117.87,100.71,96.53,33.20,29.11,6.60,6.55.HRMS(ESI)m / z:[M+H] + Calcd for C 23 H 20 IN2O3 + 499.0514; Found 499.0510.

[0075] Example 4

[0076] In this embodiment, Ar is phenyl, R 1 is adamantyl, R 2is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((((3s, 5s, 7s)-adamantan-1-yl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0077] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of adamantane (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((((3s, 5s, 7s)-adamantan-1-yl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 85%.

[0078] 1 H NMR(400MHz, CDCl3) δ10.38(d,J=13.5Hz,1H),7.91(dd,J=7.7,1.6Hz,1H),7.80(d,J=8 .6Hz,2H),7.72(d,J=8.5Hz,2H),7.42–7.35(m,1H),7.04(t,J=7.5Hz,1H),6.90(d,J=5. 6Hz,2H),6.73(d,J=13.3Hz,1H),5.14(t,J=7.2Hz,1H),3.30(dd,J=15.0,7.3Hz,1H),3. 01(dd,J=15.0,7.0Hz,1H),2.06(s,3H),1.66(d,J=12.1Hz,9H),1.55(d,J=11.9Hz,3H). 13 C NMR (100MHz, CDCl3) δ179.80,160.40,156.48,149.25,145.60,137.99,133.76,127.57,127.03,126.42, 126.14,123.33,121.59,117.75,99.13,96.47,52.60,43.17,35.82,33.22,29.25.HRMS(ESI)m / z:[M+H] + Calcd for C 30 H30 IN2O3 + 593.1296; Found 593.1295.

[0079] Example 5

[0080] In this embodiment, Ar is phenyl, R 1 is 2,6-dimethylphenyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-(((2,6-dimethylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0081] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of 2,6-dimethylaniline (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-(((2,6-dimethylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 67%.

[0082] 1 H NMR (400MHz, CDCl3) δ11.35(d,J=12.4Hz,1H),7.98(dd,J=7.8,1.6Hz,1H),7.77(d,J=8.5Hz,2H),7.68(d,J=8.5Hz,2H),7.48–7.38(m,1H),7.10–7.01 (m,4H),6.95(d,J=8.3Hz,2H),6.76(d,J=12.5Hz,1H),5.21(t,J=7.0Hz,1H ), 3.36 (dd, J=15.2, 7.3Hz, 1H), 3.10 (dd, J=15.2, 6.7Hz, 1H), 2.21 (s, 6H). 13C NMR (100MHz, CDCl3) δ181.72,160.54,157.07,148.82,138.12,137.99,134.51,132.31,128.90,127.5 7,126.95,126.54,126.38,123.09,121.82,117.99,101.67,96.56,33.14,18.57.HRMS(ESI)m / z:[M+H] + Calcdfor C 28 H 24 IN2O3 + 563.0827; Found 563.0825.

[0083] Example 6

[0084] In this embodiment, Ar is phenyl, R 1 is 2-tert-butylphenyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0085] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of 2-tert-butylaniline (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 84%.

[0086] 1H NMR (400MHz, CDCl3) δ11.98(d,J=11.7Hz,1H),7.99(dd,J=7.8,1.5Hz,1H),7.77(d,J=8 .5Hz,2H),7.70(d,J=8.5Hz,2H),7.46–7.41(m,1H),7.39(dd,J=7.5,1.7Hz,1H),7.12(t d,J=7.2,1.7Hz,2H),7.05(dd,J=13.6,7.3Hz,2H),6.93(dt,J=7.3,4.6Hz,3H),5.29(t ,J=6.9Hz,1H),3.39(dd,J=15.2,7.5Hz,1H),3.12(dd,J=15.2,6.5Hz,1H),1.49(s,9H). 13 C NMR (100MHz, CDCl3) δ181.45,160.57,157.21,148.82,143.89,140.66,139.10,137.97,134.60,127.60,127.38,1 26.99,126.67,125.17,122.86,121.77,120.25,117.99,103.57,96.51,34.60,33.19,30.28.HRMS(ESI)m / z:[M+H] + Calcd for C 30 H 28 IN2O3 + 591.1140; Found 591.1138.

[0087] Example 7

[0088] In this embodiment, Ar is phenyl, R 1 is 2,4,6-trimethylphenyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((m-trimethylamino)methylene)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0089] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of 2,4,6-trimethylaniline (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((m-trimethylamino)methylene)benzopyran-4-one was finally obtained with a yield of 69%.

[0090] 1 H NMR (400MHz, CDCl3) δ11.28(d,J=12.5Hz,1H),7.97(d,J=7.7Hz,1H),7.77( d,J=8.3Hz,2H),7.68(d,J=8.3Hz,2H),7.43(t,J=7.7Hz,1H),7.07(d,J=7.4 Hz,1H),6.95(d,J=8.5Hz,2H),6.85(s,2H),5.21(t,J=7.0Hz,1H),3.35(dd, J=15.2,7.3Hz,1H),3.10(dd,J=15.2,6.7Hz,1H),2.25(s,3H),2.17(s,6H). 13 C NMR (100MHz, CDCl3) δ181.56,160.52,157.02,149.22,148.85,137.97,136.18,135.63,134.41,132.29,1 29.47,127.56,126.50,123.15,121.78,117.95,101.42,96.50,33.15,20.80,18.41.HRMS(ESI)m / z:[M+H] + Calcd for C 29 H 26 IN2O3 + Found 577.0983.

[0091] Example 8

[0092] In this embodiment, Ar is phenyl, R 1 is 2,6-diisopropylphenyl, R 2is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0093] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of 2,6-diisopropylaniline (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 85%.

[0094] 1 H NMR(400MHz, CDCl3)δ11.24(d,J=12.4Hz,1H),7.95–7.87(m,1H),7.70(d,J=8.4Hz,2H) ,7.61(d,J=8.4Hz,2H),7.42–7.33(m,1H),7.16(s,1H),7.06(dd,J=13.9,5.5Hz,2H),7. 01(t,J=7.4Hz,1H),6.91–6.82(m,2H),6.60(d,J=12.5Hz,1H),5.14(t,J=6.9Hz,1H),3. 29(dd,J=15.3,7.6Hz,1H), 3.00(dd,J=13.8,6.8Hz,3H), 1.09(dd,J=11.7,6.8Hz,12H). 13 C NMR (100MHz, CDCl3) δ180.70,159.48,156.06,149.14,147.73,143.57,136.95,134.70,133.45,126.90,126.56,1 25.95,125.53,153.36,122.83,122.12,120.78,116.95,100.46,95.45,32.20,27.38,22.69.HRMS(ESI)m / z:[M+H] + Calcd for C32 H 32 IN2O3 + 619.1453; Found 619.1450.

[0095] Example 9

[0096] In this embodiment, Ar is 6-methylphenyl, R 1 is tert-butyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-6-methylbenzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0097] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation to obtain the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-6-methylbenzopyran-4-one with a yield of 79%.

[0098] 1 H NMR (400MHz, CDCl3) δ10.47–10.35(m,1H),7.80(d,J=8.6Hz,2H),7.75–7.67(m,3H),7.20(dd,J=8.3,1.9Hz,1H),6.90(s,1H),6.81(d,J=8.3Hz ,1H),6.71(d,J=13.1Hz,1H),5.11(t,J=7.1Hz,1H),3.30(ddd,J=15.1,7.5,0.6Hz,1H),2.99(dd,J=15.3,6.6Hz,1H),2.33(s,3H),1.23(s,9H). 13C NMR (100MHz, CDCl3) δ180.30,160.40,154.39,149.31,146.35,137.98,134.74,130.97,128.61,127.56, 127.03,126.34,126.05,122.91,117.58,99.62,96.44,52.41,33.13,29.96,20.59.HRMS(ESI)m / z:[M+H] + Calcdfor C 25 H 26 IN2O3 + 529.0983; Found 529.0982.

[0099] Example 10

[0100] In this embodiment, Ar is 6-bromophenyl, R 1 is tert-butyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-6-bromo-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0101] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-6-bromo-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 83%.

[0102] 1H NMR (400MHz, CDCl3) δ10.45(d,J=13.1Hz,1H),8.01(d,J=2.5Hz,1H),7.80(d,J=8.5Hz,2H),7.71(d,J=8.5Hz,2H),7.46(dd,J=8.7,2.5Hz,1H),6.9 0(s,1H),6.84–6.75(m,1H),6.73(d,J=13.3Hz,1H),5.15(t,J=7.2Hz,1H) ,3.29(dd,J=15.2,7.5Hz,1H),2.99(dd,J=15.1,6.8Hz,1H),1.24(s,9H). 13 C NMR (100MHz, CDCl3) δ178.44,160.55,155.42,148.86,146.92,138.03,136.37,128.86,127.56,1 26.93,126.46,124.76,119.74,114.20,98.94,96.58,52.70,33.28,29.92.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 23 BrIN2O3 + 592.9932; Found 592.9930.

[0103] Embodiment 11

[0104] In this embodiment, Ar is 6-chlorophenyl, R 1 is tert-butyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0105] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 81%.

[0106] 1 H NMR (400MHz, CDCl3) δ10.43(d,J=12.9Hz,1H),7.78(dd,J=6.3,2.8Hz,2H),7.70(s,2H),7.52–7.47(m,1H),7.35–7.28(m,1H),6.91–6. 81(m,2H),6.74(d,J=13.3Hz,1H),5.14(dd,J=9.3,4.8Hz,1H),3.27(dd,J=14.8,7.3Hz,1H),2.97(dd,J=15.0,6.3Hz,1H),1.22(s,9H). 13 C NMR (100MHz, CDCl3) δ178.53,160.50,154.92,148.88,146.95,138.00,137.78,133.51,128.67,127.54, 126.91,126.42,125.76,124.30,119.33,99.00,96.60,71.98,52.70,33.24,29.90.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 23 ClIN2O3 + 549.0437; Found 549.0436.

[0107] Example 12

[0108] In this embodiment, Ar is 6-chloro-7-methylphenyl, R 1 is tert-butyl, R 2is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-7-methylbenzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0109] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-7-methylbenzopyran-4-one was finally obtained with a yield of 77%.

[0110] 1 H NMR (400MHz, CDCl3) δ10.36–10.23(m,1H),7.77(s,1H),7.76–7.71(m,2H),7.67–7.62(m,2H),6.84(s,1H),6.72(s,1H),6.64( d,J=13.2Hz,1H),5.05(t,J=7.2Hz,1H),3.22(dd,J=15.2,7.5Hz,1H),2.91(dd,J=15.1,6.7Hz,1H),2.29(s,3H),1.17(s,9H). 13 C NMR (100MHz, CDCl3) δ178.85,160.50,154.82,149.02,146.54,142.35,138.01,127.56,126.98, 126.39,126.14,122.38,119.93,99.01,96.50,52.56,33.27,29.93,20.54.HRMS(ESI)m / z:[M+H] + Calcd for C 25 H 25 ClIN2O3 + 563.0593; Found 563.0590.

[0111] Example 13

[0112] In this embodiment, Ar is 6-fluorophenyl, R 1 is tert-butyl, R 2 is 4-iodophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-6-fluoro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0113] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-6-fluoro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 80%.

[0114] 1 H NMR (400MHz, CDCl3) δ10.37(d,J=12.9Hz,1H),7.75–7.71(m,2H),7.64(d,J=8.0Hz,2H),7.50(dd,J=8.4,2.7Hz,1H),7.19(s,1H),6.8 4(s,1H),6.79(dd,J=8.7,4.1Hz,1H),5.06(t,J=7.1Hz,1H),3.22(dd,J=15.0,7.5Hz,1H),2.92(dd,J=15.1,6.8Hz,1H),1.17(s,9H). 13 C NMR (100MHz, CDCl3) δ178.62,160.74,160.27,156.53,152.32,148.92,147.09,138.31,127.61,126. 72,125.95,119.00,118.78,111.90,111.48,99.05,96.76,52.70,33.12,29.92.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 23 FIN2O3 + 533.0732; Found 533.0730.

[0115] Embodiment 14

[0116] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 4-fluorophenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-fluorophenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0117] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-fluorophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 78%.

[0118] 1 H NMR(400MHz, CDCl3)δ10.34(d,J=13.1Hz,1H),7.98–7.87(m,2H),7.84(dd,J=7.8 ,1.6Hz,1H),7.31(ddd,J=8.3,7.3,1.7Hz,1H),7.12–7.01(m,2H),6.97(td,J=7. 8,1.0Hz,1H),6.83(dd,J=9.2,1.6Hz,2H),6.64(d,J=13.2Hz,1H),5.07(t,J=7.1 Hz, 1H), 3.23 (dd, J=15.1, 7.3Hz, 1H), 2.94 (dd, J=15.1, 6.9Hz, 1H), 1.15 (s, 9H). 13C NMR (100MHz, CDCl3) δ180.05,165.22,162.72,160.37,156.53,148.92,146.48,133.83,128.28,126.13,1 25.97,123.77,123.27,121.59,117.77,116.08,115.86,99.41,52.45,33.20,29.91.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 24 FN2O3 + 407.1766; Found 407.1764.

[0119] Embodiment 15

[0120] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 4-trifluoromethylphenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0121] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 81%.

[0122] 1H NMR (400MHz, CDCl3) δ10.44(d,J=13.1Hz,1H),8.11(d,J=8.1Hz,2H),7.92(dd ,J=7.7,1.6Hz,1H),7.71(d,J=8.3Hz,2H),7.48–7.33(m,1H),7.13–7.02(m,1H ),6.96(s,1H),6.92(d,J=8.2Hz,1H),6.75(d,J=13.2Hz,1H),5.17(t,J=7.1Hz ,1H),3.35(dd,J=15.1,7.6Hz,1H),3.03(dd,J=15.1,6.6Hz,1H),1.24(s,9H). 13 C NMR (100MHz, CDCl3) δ180.07,159.76,156.52,149.81,146.37,133.84,130.67,126.65,126.2 7,126.15,125.80,123.28,121.60,117.75,99.45,52.44,33.28,29.90.HRMS(ESI)m / z:[M+H] + Calcd for C 25 H 24 F3N2O3 + Found 457.1734.

[0123] Example 16

[0124] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 The chromanone compound of this embodiment is piperonyl, that is, (Z)-2-((2-(benzo[d][1,3]dioxol-5-yl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0125] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-2-((2-(benzo[d][1,3]dioxol-5-yl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one was finally obtained with a yield of 86%.

[0126] 1 H NMR(400MHz, CDCl3) δ10.44(d,J=12.9Hz,1H),7.93(dd,J=7.8,1.6Hz,1H),7.65 –7.56(m,1H),7.49(d,J=1.5Hz,1H),7.41(ddd,J=8.3,7.3,1.7Hz,1H),7.11–7.0 3(m,1H),6.97–6.85(m,3H),6.74(d,J=13.2Hz,1H),6.05(s,2H),5.16(t,J=7.0 Hz, 1H), 3.32 (dd, J=15.0, 7.2Hz, 1H), 3.01 (dd, J=15.0, 6.8Hz, 1H), 1.26 (s, 9H). 13 C NMR (100MHz, CDCl3) δ180.11,156.52,148.15,146.54,133.84,126.13,125.41,123.29,121.89,1 21.70,121.36,117.79,108.66,106.56,101.60,99.41,52.48,33.24,29.95.HRMS(ESI)m / z:[M+H] + Calcd for C 25 H 25 N2O5 + 433.1758; Found 433.1753.

[0127] Embodiment 17

[0128] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2is n-heptyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-heptyloxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0129] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-heptyloxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 75%.

[0130] 1 H NMR(400MHz, CDCl3)δ10.35(d,J=13.1Hz,1H),7.82(dd,J=7.8,1.7Hz,1H),7.38–7.24(m,1 H),6.96(t,J=7.5Hz,1H),6.81(d,J=8.2Hz,1H),6.64(d,J=14.8Hz,2H),5.01(t,J=7.1Hz,1 H),3.22–3.05(m,1H),2.82(dd,J=15.1,6.7Hz,1H),2.68(dd,J=19.4,11.7Hz,2H),1.67(dd ,J=15.0,7.4Hz,2H),1.27(ddd,J=9.5,8.7,4.9Hz,8H),1.22(s,9H),0.82(t,J=6.8Hz,3H). 13 C NMR (100MHz, CDCl3) δ180.12,164.56,156.58,148.27,146.47,133.80,126.10,123.79,123.30,121.5 4,117.75,99.54,52.46,33.14,31.38,30.01,28.80,28.07,26.94,22.46,13.99.HRMS(ESI)m / z:[M+H] + Calcd for C 25 H 35 N2O3 +Found 411.2643.

[0131] Embodiment 18

[0132] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is cyclohexyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-cyclohexyloxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0133] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-cyclohexyloxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 73%.

[0134] 1 H NMR (400MHz, CDCl3) δ10.35(d,J=13.0Hz,1H),7.82(dd,J=7.7,1.7Hz,1H),7.30(ddd,J=8.3,7. 3,1.7Hz,1H),7.01–6.90(m,1H),6.82(d,J=8.2Hz,1H),6.65–6.56(m,2H),5.00(t,J=7.1Hz,1H) ,3.13(dd,J=15.1,7.3Hz,1H),2.82(dd,J=15.1,6.8Hz,1H),2.76–2.64(m,1H),2.01–1.94(m,2H ),1.75(d,J=12.0Hz,2H),1.68–1.60(m,1H),1.54–1.43(m,2H),1.32–1.24(m,3H),1.22(s,9H). 13C NMR (100MHz, CDCl3) δ180.10,167.65,156.60,146.45,133.78,126.09,123.75,121.52 ,117.75,99.55,52.45,37.45,33.15,30.54,30.00,25.73,25.58.HRMS(ESI)m / z:[M+H] + Calcd for C 25 H 31 N2O3 + 395.2330; Found 395.2326.

[0135] Embodiment 19

[0136] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 2-thienyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(thien-2-yl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0137] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(thiophene-2-yl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 81%.

[0138] 1H NMR (400MHz, CDCl3) δ10.35 (d, J=13.0Hz, 1H), 7.84 (dd, J=7.7, 1.5Hz, 1H), 7.56 (dd,J=3.2,2.2Hz,1H),7.37–7.24(m,2H),7.02(m,1H),6.96(dd,J=10.6,4.4Hz ,1H),6.84(d,J=8.2Hz,1H),6.77(s,1H),6.66(d,J=13.2Hz,1H),5.07(t,J=7.2 Hz, 1H), 3.22 (dd, J=15.1, 7.4Hz, 1H), 2.91 (dd, J=15.0, 6.9Hz, 1H), 1.16 (s, 9H). 13 C NMR (100MHz, CDCl3) δ180.02,157.37,156.52,148.38,146.56,133.83,130.01,128.03,127.91,127.39 ,127.39(s),126.11,125.95,123.30,121.59,117.84,99.41,52.47,33.14,29.92.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 23 N2O3S + 395.1424; Found 395.1422.

[0139] Embodiment 20

[0140] In this embodiment, Ar is phenyl, R 1 is 2,6-diisopropylphenyl, R 2 is 4-trifluoromethylphenyl, that is, the chromanone compound of this embodiment is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)-benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0141] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)-benzopyran-4-one was finally obtained with a yield of 78%.

[0142] 1 H NMR (400MHz, CDCl3) δ11.32(d,J=12.4Hz,1H),8.08(d,J=8.2Hz,2H),7.99(dd,J=7.8,1.6Hz,1 H),7.69(d,J=8.3Hz,2H),7.48–7.40(m,1H),7.25(d,J=8.1Hz,1H),7.16(d,J=7.7Hz,2H),7.0 9(dd,J=11.0,4.0Hz,1H),7.01–6.93(m,2H),6.69(d,J=12.5Hz,1H),5.23(t,J=6.9Hz,1H),3. 40(dd,J=15.3,7.6Hz,1H), 3.10(ddd,J=13.7,7.7,5.3Hz,3H), 1.17(dd,J=12.2,6.8Hz,12H). 13 C NMR (100MHz, CDCl3) δ181.72,159.85,157.06,150.16,149.36,144.59,135.71,134.50,127.95,126.67,12 6.56,126.30,125.82,123.86,123.13,121.84,117.96,101.44,33.24,28.41,23.71.HRMS(ESI)m / z:[M+H] + Calcdfor C 32 H 32 F3N2O3 + 561.2630;Found 561.2629.

[0143] Embodiment 21

[0144] In this embodiment, Ar is phenyl, R 1 is 2,4,6-trimethylphenyl, R 2 is 4-trifluoromethylphenyl, that is, the chromanone compound of this embodiment is (Z)-3-((m-trimethylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0145] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((m-trimethylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 73%.

[0146] 1 H NMR (400MHz, CDCl3) δ11.28(d,J=12.5Hz,1H),8.08(d,J=8.2Hz,2H),7.98(dd,J=7. 8,1.6Hz,1H),7.70(d,J=8.3Hz,2H),7.47–7.41(m,1H),7.08(t,J=7.1Hz,1H),7.01– 6.93(m,2H),6.87(d,J=7.5Hz,2H),6.74(d,J=12.5Hz,1H),5.23(t,J=7.0Hz,1H),3 .39(dd,J=15.3,7.4Hz,1H),3.13(dd,J=15.2,6.6Hz,1H),2.25(s,3H),2.18(s,6H). 13 CNMR (100MHz, CDCl3) δ181.56,157.00,149.46,149.21,136.24,135.62,134.44,132.30,129.47,126.7 2,126.52,126.29,125.79,123.13,121.82,117.94,101.39,33.18,20.77,18.40.HRMS(ESI)m / z:[M+H] +Calcd for C 30 H 26 F3N2O3 + 519.1891; Found 519.190.

[0147] Embodiment 22

[0148] In this embodiment, Ar is phenyl, R 1 is 2-tert-butylphenyl, R 2 is 4-trifluoromethylphenyl, that is, the chromanone compound of this embodiment is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0149] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 82%.

[0150] 1 H NMR (400MHz, CDCl3) δ11.99(d,J=11.8Hz,1H),8.09(d,J=8.2Hz,2H),8.00(dd, J=7.8,1.6Hz,1H),7.69(d,J=8.3Hz,2H),7.48–7.41(m,1H),7.39(dd,J=7.5,1 .8Hz,1H),7.16–7.04(m,4H),7.00(s,1H),6.98–6.91(m,2H),5.31(t,J=6.9Hz ,1H),3.42(dd,J=15.3,7.5Hz,1H),3.15(dd,J=15.3,6.3Hz,1H),1.49(s,9H). 13C NMR (100MHz, CDCl3) δ181.45,159.92,157.18,149.42,143.86,140.67,139.08,134.64,130.58,127.36,127.02,126.8 0,126.68,126.33,125.82,125.19,122.85,121.81,120.20,117.98,103.55,34.60,33.22,30.26.HRMS(ESI)m / z:[M+H] + Calcd for C 31 H 28 F3N2O3 + 533.2047;Found 533.2043.

[0151] Embodiment 23

[0152] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 4-(p-tolueneacetyl)phenyl, that is, the chromanone compound of this embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(p-tolueneacetyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0153] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(p-tolueneacetyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 86%.

[0154] 1H NMR(400MHz, CDCl3)δ10.34(d,J=13.0Hz,1H),7.99–7.77(m,3H),7.59–7.45(m,2H),7.39–7.25(m,3H),7.11–7.03(m,2H),6.99–6.91(m,1H) ), 6.83(dd,J=7.1,3.4Hz,2H),6.67–6.57(m,1H),5.13–5.01(m,1H),3.29–3.16(m,1H),3.00–2.86(m,1H),2.27(s,3H),1.18–1.09(m,9H). 13 C NMR (100MHz, CDCl3) δ180.03,160.70,156.57,149.08,146.53,138.79,133.84,131.91,131.57,129.20,126.81,126.51,126 .19,125.93,125.30,123.30,121.59,119.85,117.81,99.42,91.86,88.38,52.45,33.25,29.93,21.53.HRMS(ESI)m / z:[M+H] + Calcd for C 33 H 31 N2O3 + 503.2330; Found 503.2326.

[0155] Embodiment 24

[0156] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2 is 4-(N,N-dipropylaminosulfonyl)phenyl, that is, the chromanone compound of this embodiment is (Z)-4-(5-((3-((tert-butylamino)methylene)-4-oxo-2-yl)methyl)oxazol-2-yl)-N,N-dipropylbenzenesulfonamide, and the specific steps of its synthesis method are as follows:

[0157] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL) and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again and reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation, and the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one was finally obtained with a yield of 71%.

[0158] 1 H NMR (400MHz, CDCl3) δ10.44(d,J=13.1Hz,1H),8.12(d,J=8.5Hz,2H),7.95–7.83(m,3H),7. 44–7.35(m,1H),7.05(t,J=7.5Hz,1H),6.98(s,1H),6.91(d,J=8.2Hz,1H),6.76(d,J=13.2H z,1H),5.17(t,J=7.1Hz,1H),3.35(dd,J=15.2,7.7Hz,1H),3.12(dd,J=9.9,5.4Hz,4H),3.0 3(dd,J=15.2,6.5Hz,1H),1.56(dd,J=15.1,7.5Hz,4H),1.25(s,9H),0.88(t,J=7.4Hz,6H). 13 C NMR (100MHz, CDCl3) δ180.07,159.65,156.47,150.02,146.47,141.52,133.90,130.76,127.54,126.74,126 .46,126.17,123.25,121.65,117.77,99.43,52.52,49.87,33.30,29.95,21.89,11.17.HRMS(ESI)m / z:[M+H] + Calcd for C 30 H 38 N3O5S + 552.2527; Found 552.2526.

[0159] Embodiment 25

[0160] In this embodiment, Ar is phenyl, R1 is tert-butyl, R 2 The chromanone compound of the present embodiment is 4-(((8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-17-yl)ethynyl)phenyl, that is, the chromanone compound of the present embodiment is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(((8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-17-yl)ethynyl)phenyl)oxazol-5-yl)methyl)chroman-4-one, and the specific steps of its synthesis method are as follows:

[0161] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL), and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation to obtain the target product (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(((8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-17-yl)ethynyl)phenyl)oxazol-5-yl)methyl)chrom-4-one with a yield of 75%.

[0162] 1H NMR (400MHz, CDCl3) δ10.35(d,J=13.2Hz,1H),7.90–7.82(m,3H),7.42(d,J=8.4Hz,2H),7.35–7.27(m,1H),7.06(d,J=8.5Hz,1H),6.96(d d,J=11.0,4.0Hz,1H),6.87(s,1H),6.83(d,J=7.9Hz,1H),6.67(d,J=13.2Hz,1H),6.59(dd,J=8.4,2.6Hz,1H),6.52(d,J=2.5Hz,1H),5.0 8(t,J=7.1Hz,1H),3.25(dd,J=15.1,7.5Hz,1H),2.93(dd,J=15.1,6.6Hz,1H),2.72(q,J=11.2Hz,2H),2.40–2.25(m,2H),2.16(dd,J=14. 9,7.2Hz,1H),2.03(dd,J=18.2,8.2Hz,1H),1.89(td,J=12.8,3.7Hz,1H),1.82–1.64(m,4H),1.45–1.28(m,4H),1.15(s,9H),0.86(s,3H). 13 C NMR (100MHz, CDCl3) δ180.08,162.75,160.69,156.49,154.11,149.28,146.68,138.09,1 33.94,132.11,131.92,126.45,126.22,126.11,125.98,125.03,123.23,121.69,117.81, 115.39,112.88,99.44,95.33,85.45,80.42,52.57,49.93,47.76,43.69,39.56,39.13,36 .58,33.27,33.19,31.57,29.94,29.68,27.29,26.52,22.99,12.95.HRMS(ESI)m / z:[M+H] + Calcd for C 44 H 47 N2O5 + 683.3480; Found 683.3479.

[0163] Embodiment 26

[0164] In this embodiment, Ar is phenyl, R 1 is tert-butyl, R 2The chromanone compound of this embodiment is (Z)-2-((2-(4-((3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethynyl)phenyl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one, and the specific steps of its synthesis method are as follows:

[0165] Chromone-3-carboxaldehyde (0.2mmol) was slowly added to a mixed solution of tert-butylamine (0.2mmol) and DCE (2.0mL), and stirred at room temperature for 10 minutes. Subsequently, 4-iodo-N-(prop-2-yn-1-yl)benzamide (0.24mmol) and Zn(OTf)2 (20mol%) were added to the reaction system again, and the mixture was reacted in an oil bath at 100°C for 5 hours. The reaction was detected by thin layer chromatography. After the reaction was completed, dichloromethane liquid was added to the reaction system three times for extraction, 20mL each time, and then washed twice with saturated brine. The organic phase was dried over anhydrous sodium sulfate to obtain a crude product. Silica gel column was used for separation to obtain the target product (Z)-2-((2-(4-((3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethynyl)phenyl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one with a yield of 79%.

[0166] 1 H NMR (400MHz, CDCl3) δ10.35(d,J=13.2Hz,1H),8.51(s,1H),7.89(d,J=8.4Hz,3H),7.85(dd,J=7.8,1.6Hz,1H) ,7.70(d,J=7.8Hz,1H),7.51(d,J=8.4Hz,2H),7.37(s,1H),7.33–7.23(m,3H),7.11(s,1H),6.99–6.92(m,1H), 6.84(d,J=6.7Hz,2H),6.66(d,J=13.2Hz,1H),5.09(t,J=7.1Hz,1H),4.23–4.17(m,2H),4.16–4.10(m,2H),3.7 2(dd,J=9.2,5.3Hz,4H),3.36(s,6H),3.25(dd,J=15.3,7.4Hz,1H),2.95(dd,J=15.2,6.8Hz,1H),1.14(s,9H). 13C NMR (100MHz, CDCl3) δ180.07,160.63,156.59,154.91,149.18,146.64,138.7 2,133.90,132.03,129.05,127.65,127.01,126.48,126.13,125.94,124.92,1 23.58,123.26,122.44,121.63,117.83,108.87,103.03,99.46,91.32,89.21, 70.87,70.41,69.28,68.48,59.28,52.53,33.27,29.92.HRMS(ESI)m / z:[M+H] + Calcd for C 46 H 46 N5O7 + 780.3392; Found 780.3388.

[0167] Biological activity test experiment

[0168] The biological activity tests of the chromanone compounds prepared in Examples 1-26 were performed as follows:

[0169] DU145 and HCT116 cells were cultured in high-glucose medium supplemented with 10% fetal bovine serum. All cells were cultured at 37°C, 5% CO2 and a humidified environment. After counting, tumor cells were counted at 3×10 per well. 3 The cells were inoculated into a 96-well plate containing 100 μL complete medium at a density of 10 cells. After culturing for 24 hours, 100 μL complete medium containing 10 μM chromanone compounds prepared in Examples 1-26 and an equal amount of dimethyl sulfoxide (DMSO) were added, and each treatment was repeated three times. The treated cells were cultured for another 72 hours, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide was added, and the plate was cultured for another 4 hours. After the culture was completed, the culture medium was removed and 150 μL DMSO was added to each well to dissolve the formazan. The optical density (OD) of each well was measured at an absorbance wavelength of 570 nm using a microplate reader (Bio-Tek, Winosky, USA). The survival rate of the treated cells was calculated, and the optical density of the compound treatment was compared with the optical density of the DMSO treatment to obtain the survival rate. The measurement results are shown in Table 1:

[0170]

[0171]

[0172] Table 1

[0173] The data in Table 1 show that the chromanone compounds containing 1,3-oxazole fragments of the present invention have a significant inhibitory effect on the cell activity of human prostate cancer cells DU145 and human colon cancer cells HCT116. After treatment with chromanone compounds, the survival rate of human prostate cancer cells DU145 is as low as 47%, and the survival rate of human colon cancer cells HCT116 is as low as 64%. Therefore, the chromanone derivatives containing 1,3-oxazole fragments of the present invention can be used to prepare antitumor drugs, especially for preparing drugs for treating prostate cancer and colon cancer. Among them, the antitumor drug comprises a chromanone derivative containing a 1,3-oxazole fragment or a pharmaceutically acceptable salt, hydrate or combination thereof and excipients, and the antitumor drug can be any one of granules, tablets, pills, capsules, injections or dispersants.

[0174] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should be included in the scope of the claims of the present invention. The techniques, shapes, and structural parts not described in detail in the present invention are all known technologies.

Claims

1. A chromanone compound containing a 1,3-oxazole fragment, characterized in that: The general structural formula of the compound is as follows: Wherein, Ar is a phenyl group which is unsubstituted or substituted with a first substituent, the first substituent substitution includes mono-substitution or di-substitution, and the first substituent is selected from halogen and an alkyl group having 1 to 6 carbon atoms; R 1 A phenyl group substituted with a second substituent, or a straight-chain or branched alkyl group having 3 to 10 carbon atoms, or a cycloalkyl group having 3 to 10 carbon atoms, wherein the second substituent includes di-substitution or tri-substitution, and the second substituent is selected from an alkyl group having 1 to 6 carbon atoms; R 2 It is one of alkyl, aryl and heteroaryl.

2. The chromanone compound containing a 1,3-oxazole fragment according to claim 1, characterized in that: Ar is selected from phenyl, 6-methylphenyl, 6-bromophenyl, 6-chlorophenyl, 6-chloro-7-methylphenyl, 6-fluorophenyl; R 1 Selected from tert-butyl, isopropyl, cyclopropyl, adamantyl, 2,6-dimethylphenyl, 2-tert-butylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl; R 2 Selected from 4-iodophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, piperonyl, n-heptyl, cyclohexyl, 2-thienyl, 4-trifluoromethylphenyl.

3. The chromanone compound containing a 1,3-oxazole fragment according to claim 2, characterized in that: The compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((isopropylamino)methylene)benzopyran-4-one; Alternatively, the compound is (Z)-3-((cyclopropylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((((3s,5s,7s)-adamantan-1-yl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-(((2,6-dimethylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-3-((m-trimethylamino)methylene)benzopyran-4-one; Alternatively, the compound is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-6-methylbenzopyran-4-one; Alternatively, the compound is (Z)-6-bromo-3-((tert-butylamino)methylene)-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-chloro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)-7-methylbenzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-6-fluoro-2-((2-(4-iodophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-fluorophenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-2-((2-(benzo[d][1,3]dioxol-5-yl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-heptyloxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-cyclohexyloxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(thiophen-2-yl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-(((2,6-diisopropylphenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)-benzopyran-4-one; Alternatively, the compound is (Z)-3-((m-trimethylamino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-(((2-(tert-butyl)phenyl)amino)methylene)-2-((2-(4-(trifluoromethyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(p-tolueneacetyl)phenyl)oxazol-5-yl)methyl)benzopyran-4-one; Alternatively, the compound is (Z)-4-(5-((3-((tert-butylamino)methylene)-4-oxo-2-yl)methyl)oxazol-2-yl)-N,N-dipropylbenzenesulfonamide; Alternatively, the compound is (Z)-3-((tert-butylamino)methylene)-2-((2-(4-(((8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-17-yl)ethynyl)phenyl)oxazol-5-yl)methyl)chrom-4-one; Alternatively, the compound is (Z)-2-((2-(4-((3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethynyl)phenyl)oxazol-5-yl)methyl)-3-((tert-butylamino)methylene)benzopyran-4-one.

4. A method for synthesizing chromanone compounds containing 1,3-oxazole fragments, characterized in that: The synthesis method is as follows: Wherein, Ar is selected from phenyl, 6-methylphenyl, 6-bromophenyl, 6-chlorophenyl, 6-chloro-7-methylphenyl, 6-fluorophenyl; R 1 Selected from tert-butyl, isopropyl, cyclopropyl, adamantyl, 2,6-dimethylphenyl, 2-tert-butylphenyl, 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl; R 2 Selected from 4-iodophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, piperonyl, n-heptyl, cyclohexyl, 2-thienyl, 4-trifluoromethylphenyl.

5. The synthesis method according to claim 4, characterized in that The synthesis method is as follows: Compound 1 is added to a mixed solution of compound 2 and dichloroethane, and stirred at room temperature for 5 to 20 minutes. Compound 3 and Zn(OTf)2 are then added to the reaction system, and the mixture is reacted at 90 to 110°C for 3 to 6 hours. The reaction is detected by thin layer chromatography. After the reaction is completed, dichloromethane is added, and the mixture is washed with saturated brine. The organic phase is dried over anhydrous sodium sulfate to obtain a crude product, which is separated using a silica gel column to obtain a chromanone compound containing a 1,3-oxazole fragment.

6. The synthesis method according to claim 5, characterized in that The molar ratio of the compound 1, the compound 2 and the compound 3 is 1:1:(1.1-1.3).

7. Use of the chromanone compound containing a 1,3-oxazole fragment according to any one of claims 1 to 3 or the chromanone compound containing a 1,3-oxazole fragment synthesized according to the synthesis method according to any one of claims 4 to 6 in the preparation of antitumor drugs.

Citation Information

Cited By

  • 12-aryl-11H-benzo [b] indeno [1, 2-e] [1, 4] oxazapine compound as well as preparation method and application thereof

    CN120987869A